Skip to main content
SpringerLink
Log in

Dalbavancin in acute bacterial skin infections: higher cost, higher readmission rates

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Gonzalez J, et al. Cost-consequence analysis of single-dose dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections in a multi-site healthcare system. Clinical Infectious Diseases : 19 Nov 2020. Available from: URL: http://doi.org/10.1093/cid/ciaa1732

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dalbavancin in acute bacterial skin infections: higher cost, higher readmission rates. PharmacoEcon Outcomes News 868, 11 (2020). https://doi.org/10.1007/s40274-020-7343-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-7343-y

Search

Navigation